Literature DB >> 32493814

Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19.

Jeremy K Y Yap1, Miyu Moriyama2, Akiko Iwasaki3,4,5.   

Abstract

The inflammatory response to severe acute respiratory syndrome-related coronavirus 2 infection has a direct impact on the clinical outcomes of coronavirus disease 2019 patients. Of the many innate immune pathways that are engaged by severe acute respiratory syndrome-related coronavirus 2, we highlight the importance of the inflammasome pathway. We discuss available pharmaceutical agents that target a critical component of inflammasome activation, signaling leading to cellular pyroptosis, and the downstream cytokines as a promising target for the treatment of severe coronavirus disease 2019-associated diseases.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32493814      PMCID： PMC7343621          DOI： 10.4049/jimmunol.2000513

Source DB:  PubMed          Journal:  J Immunol        ISSN： 0022-1767            Impact factor:   5.422


  62 in total

Review 1.  Gasdermins: Effectors of Pyroptosis.

Authors:  Stephen B Kovacs; Edward A Miao
Journal:  Trends Cell Biol       Date:  2017-06-12       Impact factor: 20.808

2.  RNase L activates the NLRP3 inflammasome during viral infections.

Authors:  Arindam Chakrabarti; Shuvojit Banerjee; Luigi Franchi; Yueh-Ming Loo; Michael Gale; Gabriel Núñez; Robert H Silverman
Journal:  Cell Host Microbe       Date:  2015-03-26       Impact factor: 21.023

3.  Activation of NLRP3 inflammasome in alveolar macrophages contributes to mechanical stretch-induced lung inflammation and injury.

Authors:  Jianbo Wu; Zhibo Yan; David E Schwartz; Jingui Yu; Asrar B Malik; Guochang Hu
Journal:  J Immunol       Date:  2013-02-22       Impact factor: 5.422

4.  Influenza enhances caspase-1 in bronchial epithelial cells from asthmatic volunteers and is associated with pathogenesis.

Authors:  Rebecca N Bauer; Luisa E Brighton; Loretta Mueller; Zhidan Xiang; Julia E Rager; Rebecca C Fry; David B Peden; Ilona Jaspers
Journal:  J Allergy Clin Immunol       Date:  2012-10       Impact factor: 10.793

Review 5.  Beyond the inflammasome: regulatory NOD-like receptor modulation of the host immune response following virus exposure.

Authors:  Sheryl Coutermarsh-Ott; Kristin Eden; Irving Coy Allen
Journal:  J Gen Virol       Date:  2016-01-13       Impact factor: 3.891

6.  Clinical and immunological features of severe and moderate coronavirus disease 2019.

Authors:  Guang Chen; Di Wu; Wei Guo; Yong Cao; Da Huang; Hongwu Wang; Tao Wang; Xiaoyun Zhang; Huilong Chen; Haijing Yu; Xiaoping Zhang; Minxia Zhang; Shiji Wu; Jianxin Song; Tao Chen; Meifang Han; Shusheng Li; Xiaoping Luo; Jianping Zhao; Qin Ning
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

7.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.

Authors:  Roujian Lu; Xiang Zhao; Juan Li; Peihua Niu; Bo Yang; Honglong Wu; Wenling Wang; Hao Song; Baoying Huang; Na Zhu; Yuhai Bi; Xuejun Ma; Faxian Zhan; Liang Wang; Tao Hu; Hong Zhou; Zhenhong Hu; Weimin Zhou; Li Zhao; Jing Chen; Yao Meng; Ji Wang; Yang Lin; Jianying Yuan; Zhihao Xie; Jinmin Ma; William J Liu; Dayan Wang; Wenbo Xu; Edward C Holmes; George F Gao; Guizhen Wu; Weijun Chen; Weifeng Shi; Wenjie Tan
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

Review 8.  NLRP3 Inflammasome-A Key Player in Antiviral Responses.

Authors:  Chunyuan Zhao; Wei Zhao
Journal:  Front Immunol       Date:  2020-02-18       Impact factor: 7.561

9.  Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan.

Authors:  Jasper Fuk-Woo Chan; Kin-Hang Kok; Zheng Zhu; Hin Chu; Kelvin Kai-Wang To; Shuofeng Yuan; Kwok-Yung Yuen
Journal:  Emerg Microbes Infect       Date:  2020-01-28       Impact factor: 7.163

10.  Rapid induction of inflammatory lipid mediators by the inflammasome in vivo.

Authors:  Jakob von Moltke; Norver J Trinidad; Mahtab Moayeri; Alexander F Kintzer; Samantha B Wang; Nico van Rooijen; Charles R Brown; Bryan A Krantz; Stephen H Leppla; Karsten Gronert; Russell E Vance
Journal:  Nature       Date:  2012-08-19       Impact factor: 49.962
View more
  84 in total

Review 1.  Natural Supplements for COVID19-Background, Rationale, and Clinical Trials.

Authors:  Melody Hermel; Megan Sweeney; Yu-Ming Ni; Robert Bonakdar; Douglas Triffon; Christopher Suhar; Sandeep Mehta; Sarah Dalhoumi; James Gray
Journal:  J Evid Based Integr Med       Date:  2021 Jan-Dec

Review 2.  NLRP3 inflammasome activation and SARS-CoV-2-mediated hyperinflammation, cytokine storm and neurological syndromes.

Authors:  Debashis Dutta; Jianuo Liu; Huangui Xiong
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2022-06-15

3.  Phenome-wide and expression quantitative trait locus associations of coronavirus disease 2019 genetic risk loci.

Authors:  Chang Yoon Moon; Brian M Schilder; Towfique Raj; Kuan-Lin Huang
Journal:  iScience       Date:  2021-05-18

4.  Distinct axial and lateral interactions within homologous filaments dictate the signaling specificity and order of the AIM2-ASC inflammasome.

Authors:  Mariusz Matyszewski; Weili Zheng; Jacob Lueck; Zachary Mazanek; Naveen Mohideen; Albert Y Lau; Edward H Egelman; Jungsan Sohn
Journal:  Nat Commun       Date:  2021-05-12       Impact factor: 14.919

5.  Caspases and therapeutic potential of caspase inhibitors in moderate-severe SARS-CoV-2 infection and long COVID.

Authors:  Matthew Plassmeyer; Oral Alpan; Michael J Corley; Thomas A Premeaux; Kimberleigh Lillard; Paige Coatney; Tina Vaziri; Suzan Michalsky; Alina P S Pang; Zaheer Bukhari; Stephen T Yeung; Teresa H Evering; Gail Naughton; Martin Latterich; Philip Mudd; Alfred Spada; Nicole Rindone; Denise Loizou; Søren Ulrik Sønder; Lishomwa C Ndhlovu; Raavi Gupta
Journal:  Allergy       Date:  2021-06-02       Impact factor: 14.710

Review 6.  Inflammasome regulation in driving COVID-19 severity in humans and immune tolerance in bats.

Authors:  Sahana Nagaraja; Disha Jain; Sannula Kesavardhana
Journal:  J Leukoc Biol       Date:  2021-05-31       Impact factor: 6.011

Review 7.  Infection-induced inflammation from specific inborn errors of immunity to COVID-19.

Authors:  Cheng-Lung Ku; I-Ting Chen; Ming-Zong Lai
Journal:  FEBS J       Date:  2021-05-20       Impact factor: 5.622

8.  The Immunopathobiology of SARS-CoV-2 Infection.

Authors:  Milankumar Patel; Farah Shahjin; Jacob D Cohen; Mahmudul Hasan; Jatin Machhi; Heerak Chugh; Snigdha Singh; Srijanee Das; Tanmay A Kulkarni; Jonathan Herskovitz; Douglas D Meigs; Ramesh Chandra; Kenneth S Hettie; R Lee Mosley; Bhavesh D Kevadiya; Howard E Gendelman
Journal:  FEMS Microbiol Rev       Date:  2021-11-23       Impact factor: 16.408

9.  High Levels of the Cleaved Form of Galectin-9 and Osteopontin in the Plasma Are Associated with Inflammatory Markers That Reflect the Severity of COVID-19 Pneumonia.

Authors:  Gaowa Bai; Daisuke Furushima; Toshiro Niki; Takashi Matsuba; Yosuke Maeda; Atsushi Takahashi; Toshio Hattori; Yugo Ashino
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

Review 10.  Pathogenesis of taste impairment and salivary dysfunction in COVID-19 patients.

Authors:  Yasuo Okada; Ken Yoshimura; Shuji Toya; Makoto Tsuchimochi
Journal:  Jpn Dent Sci Rev       Date:  2021-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.